Chronic Total Occlusion (CTO) is the last frontier in interventional cardiology. CTO interventions are often lengthy and demanding, require prolonged harmful fluoroscopy exposure, high contrast media loading and have an overall success rate of 60%-80%, even among experienced operators.

The NovaCross™, micro-catheter is Nitiloop's leading product indicated to be used for coronary and peripheral vasculature. NovaCross™ is an low profile micro-catheter with an expandable nitinol scaffold shaped like a loop located at the distal end of the device. The loop is easily expanded and collapsed by the operator, providing enhanced guidewire support and positioning within the artery lumen. The NovaCross™ also features a unique tip design for high crossing performance.

The NovaCross™ offers a robust "first-choice" tool for treatment of complex lesions in coronary and peripheral vasculature, specifically Below the Knee (BTK) CTOs.

The safety and efficacy of the NovaCross™ microcatheter have been evaluated in the clinical setting. To read more click here.

The proprietary Nitiloop platform is planned to be used in additional products such as Embolotherapy applications, for the treatment of liver cancer with chemotherapy or radiation beads injected through the Nitiloop micro-catheter.